Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Traditional Use of Biomarkers in Cancer Management
- Trends in Cancer Biomarker Development
- Biomarker Discovery
- Clinical Validation of Cancer Biomarkers
- Ciphergen
- Miraculins
- Panacea Pharmaceuticals
- Biomarker Technologies
- Engagement of Diagnostics Industry
- Recent Advances in Detection Technologies
- Image-Based Biomarkers
- The "omics" Platforms
- Nanodiagnostics
- Applications of Cancer Biomarkers
- Transformation of Clinical Trial Design
- Genetic Predisposition
- Screening and Early Detection of Cancer
- Diagnosis and Prognosis
- Treatment Selection and Response
- Recurrence
- Emerging Biomarkers in Select Cancers
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Roadblocks to Integrating Cancer Biomarkers into Clinical Practice
- Technical Challenges
- Lack of a Centralized Database
- Economic Challenges
- Regulatory Oversight
- Current Activities of Cancer Biomarker Companies
- Biomarker Technologies
- Ciphergen
- Claros Diagnostics
- Epigenomics
- Exagen Diagnostics
- Genesis Genomics
- Health Discovery Corporation
- Ipsogen
- Matritech
- Miraculins
- Orion Genomics
- Phenomenome Discoveries
- Power3 Medical Products
- Upstream Biosciences
Tables:
- 1. Sensitivities and Specifi cities of Select FDA-Approved Traditional
Cancer Biomarkers
- 2. FDA-Approved Cancer Biomarkers with Companion Diagnostic Tests
- 3. Select Cancer Biomarker Patent Filings
- 4. Select Issued Patents for Cancer Biomarkers in the United States
(2001-Present)
- 5. Select Nanodiagnostic Products
- 6. Available Tests for Genetic Predisposition to Cancer Development
- 7. Profi les of Companies Engaged in Cancer Biomarker Development
Figures:
- 1. Overall Five-Year Survival, by Stage
- 2. Potential Impact of Cancer Biomarkers in Drug Discovery and Drug
Development Processes
- 3. Applications of Biomarkers in Cancer Management
|
Related Report
|